Top

Reactions Weekly

Published in:

01-08-2022 | Erythroderma | Case report

Brentuximab-vedotin

Splinter nail haemorrhages and lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Filipovic N, et al. Brentuximab-induced splinter nail haemorrhages in a patient with Sezary syndrome: A case report. British Journal of Clinical Pharmacology 88: 3883-3886, No. 8, Aug 2022. Available from: URL: http://doi.org/10.1111/bcp.15247

Title: Brentuximab-vedotin
Splinter nail haemorrhages and lack of efficacy: case report
Publication date: 01-08-2022
Publisher: Springer International Publishing
Keywords: Erythroderma
Sézary Syndrome
Brentuximab vedotin
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-21094-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Brentuximab-vedotin

Splinter nail haemorrhages and lack of efficacy: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Clopidogrel/enoxaparin sodium

Escitalopram/sertraline

Immunosuppressants/heparin

Important non-serious AEs in adults prescribed antidepressants

Anticoagulants

Denosumab